Attached files
| file | filename |
|---|---|
| EX-14.1 - INVIVO THERAPEUTICS HOLDINGS CORP. | v205728_ex14-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event
reported): December 10, 2010
INVIVO
THERAPEUTICS HOLDINGS CORP.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction of incorporation)
|
000-52089
(Commission File
No.)
|
36-4528166
(IRS
Employer Identification No.)
|
|
One Broadway, 14th Floor
Cambridge,
Massachusetts
|
02142
|
|
(Address of principal
executive offices)
|
(Zip
Code)
|
(617) 475-1520
(Registrant’s
telephone number, including area code)
Design
Source, Inc., 100 Europa Drive, Suite 455, Chapel Hill, NC 27517
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.05
|
Amendments to the Registrant’s
Code of Ethics, or Waiver of a Provision of the Code of Ethics.
|
On
December 10, 2010, the Board of Directors of InVivo Therapeutics Holdings Corp.
(the “Company”) adopted a new Code of Business Conduct and Ethics (the “New Code
of Ethics”), superseding and replacing the prior Code of Ethics adopted in
2006.
The New
Code of Ethics sets forth legal and ethical standards of conduct for employees,
officers and directors of the Company and its subsidiaries, including the
Company’s principal executive officer and its senior financial officers
(principal financial officer and controller or principal accounting officer, or
persons performing similar functions). The New Code of Ethics is
intended to deter wrongdoing and to promote the conduct of all Company business
in accordance with high standards of integrity and in compliance with all
applicable laws and regulations.
The
foregoing summary is subject to and is qualified in its entirety by reference to
the full text of the New Code of Ethics, a copy of which is attached as Exhibit
14.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
The New
Code of Ethics will be posted in the “Investor Relations” section of the
Company’s website, www.invivotherapeutics.com.
|
Item 9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
The
exhibit listed in the Exhibit Index below is filed with this
report.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
| InVivo Therapeutics Holdings Corp. | |||
|
Date:
December 16, 2010
|
By:
|
/s/ Frank M. Reynolds | |
| Frank M. Reynolds | |||
| Chief Executive Officer | |||
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
| 14.1 | InVivo Therapeutics Holdings Corp. Code of Business Conduct and Ethics |